合成核蛋白病变中的α-合成核蛋白病理:机制,生物标志物和治疗挑战
Oscar Arias-Carrión1,2, Magdalena Guerra-Crespo3, Francisco J Padilla-Godínez3,4
1Experimental Neurology, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Mexico City 14389, Mexico.
International journal of molecular sciences
|June 13, 2025
概括
帕金森病和相关的同核素病变涉及α-synuclein (aSyn) 蛋白质聚合. 了解aSyn生物学,传播和系统影响是开发新生物标志物和治疗方法的关键.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 遗传学 是一个遗传学.
背景情况:
- 包括帕金森病在内的同核蛋白病变是由大脑细胞中的α-synuclein (aSyn) 蛋白聚合定义的.
- 这种聚合导致细胞功能障碍和神经退行,导致各种神经系统疾病.
研究的目的:
- 综合当前关于α-synuclein (aSyn) 生物学,聚合和传播机制的知识.
- 探索对aSyn病理学的系统影响,包括免疫反应和肠道微生物群.
- 审查生物标志物开发和同核蛋白病变治疗策略的进展.
主要方法:
- 关于aSyn生物学,聚合和传播的文献综述.
- 对影响aSyn病理的细胞和系统因素的分析.
- 评估当前和新兴的诊断生物标志物和治疗方法.
主要成果:
- aSyn聚合物表现出多样化的结构和类似菌株的特性,可能通过类似子的机制传播.
- 功能失调的蛋白质清除途径和翻译后的修改增强了aSyn积累和毒性.
- 外围因素,如肠道微生物组的改变和免疫反应,显著调节中央神经退行.
结论:
- 早期诊断和疾病监测的可靠生物标志物对于开发有效的协核蛋白病变治疗方法至关重要.
- 需要整合遗传,表观遗传和环境因素的跨学科方法来建模和治疗这些复杂的疾病.
- 对aSyn生物学及其系统相互作用的进一步研究对于推进治疗干预措施至关重要.
更多相关视频
12:01Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
10.7K
09:27Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
Published on: January 5, 2016
17.3K
相关概念视频
Parkinson's Disease: Overview
501
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
501
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
